TLR5 protein holds potential for new Alzheimer’s biotherapy

Posted: 29 August 2018 | | No comments yet

Researchers at the University of Florida have discovered that a modified version of an important immune cell protein, TLR5, could be used to treat Alzheimer’s disease.

TLR5 amyloid plaques

The study reveals that soluble versions of the TLR5 protein can reduce the buildup of amyloid plaques in the brains of Alzheimer’s disease model mice and prevent the toxic peptide that forms these plaques from killing neurons.

Alzheimer’s disease is characterised by the formation of amyloid plaques containing aggregates of a toxic protein fragment called β-amyloid that causes nerve cells in the brain to degenerate and die. The body’s immune system can influence the progression of Alzheimer’s disease in one of two ways: either reducing the buildup of β-amyloid, or responding to neuronal damage by inducing inflammation that can cause further neurodegeneration.

Toll-like receptors (TLRs) are a family of proteins on the surface of immune cells that recognise molecules released by pathogens or damaged cells and then initiate an appropriate immune response. A team of researchers at the University of Florida – led by Paramita Chakrabarty and Todd E Golde – found that the brains of Alzheimer’s disease patients had more TLRs, partly due to an increase in the number of specialised brain immune cells known as microglia.

The researchers hypothesised that untethering some of these TLRs from the surface of microglia could reduce the formation of amyloid plaques. These soluble TLRs might act as “decoy receptors” that bind to β-amyloid and limit its aggregation without initiating cellular signalling pathways that could lead to inflammation.

Chakrabartyand colleagues found that soluble versions of one TLR in particular – TLR5 – could prevent or even reverse the formation of amyloid plaques in mice that produce large amounts of human β-amyloid.

Commenting on the limitations of the findings, Chakrabarty said: “This mouse model is well recognised as a primary model for Alzheimer-type amyloid plaque deposition, but it does not recapitulate the entire Alzheimer’s neurodegenerative cascade. “Therefore, the potential of soluble TLR5 in dampening immune activation and related neurotoxic pathways needs to be further explored in multiple models of Alzheimer’s disease.”

The researchers determined that soluble TLR5 could bind to β-amyloid aggregates and enhance their uptake into microglia. It also reduced the ability of β-amyloid to kill neurons cultured in the laboratory.

“By directly interacting with β-amyloid and attenuating β-amyloid levels in mice, the soluble TLR5 decoy receptor represents a novel and potentially safe class of immunomodulatory agents for Alzheimer’s disease,” says Golde.

Study is published in the Journal of Experimental Medicine.

Related topics

Related organisations